Medical - Healthcare Plans · NYSE
目前價格
$390.11
PE Ratio (TTM)
25.1x
內在價值
$365.21
安全邊際 -6.8%
截至 2026-08-21,對 UnitedHealth Group Incorporated(UNH)每股盈餘 $15.59 套用 25.0x 的獲利倍數,得出每股公允價值估算約 $365.21,目前股價為 $390.11。
基於獲利倍數的公允價值對所選倍數很敏感。在敏感度網格上,估算區間為 $301.55 至 $438.13。這是錨定獲利的相對估算,並非事實定論。如需基於現金流的視角,請參閱 DCF 頁面的內在價值估算。
PE 模型如何運作 · 用 PE 模式重新計算 · UNH 內在價值(DCF 視角)
在 $390.11 的價格下,UNH 的交易價比其基於 PE 的公允價值估算高約 6.8%,相對所用獲利倍數屬小幅溢價,需留意獲利成長能否支撐這一價格。
競爭護城河
↑規模經濟與網絡效應
UnitedHealth Group 龐大的會員基礎和醫療服務網絡,使其在與醫療提供者議價時擁有顯著優勢。這也吸引了更多醫療提供者加入其網絡,形成正向循環。
↑數據與分析能力
公司透過 Optum 平台收集和分析海量醫療數據,能更精準地預測醫療成本、優化照護流程,並開發創新的健康管理解決方案。
↑品牌聲譽與客戶忠誠度
UnitedHealth Group 在醫療保險領域建立了強大的品牌聲譽,贏得了雇主和個人的信任。轉換成本高昂,客戶傾向於維持現有保險計劃。
投資風險
↓競爭加劇
其他大型保險公司和新興的健康科技公司正積極爭奪市場份額,可能對 UnitedHealth Group 的領導地位構成威脅。
↓醫療服務提供者關係
與醫療服務提供者之間的談判和合同關係可能變得緊張,影響其網絡的穩定性和成本控制。
↓技術變革
快速發展的醫療科技和數位化趨勢,可能顛覆現有的醫療服務和保險模式,要求公司持續投入創新以保持競爭力。
基準情形
內在價值
$365.21
安全邊際
-6.8%
預期年化報酬
-1.3%
基準情形假設:盈餘年成長率 4.3%、目標 P/E 倍數 25.02x、折現率 10%、預測 5 年。資料截至 2026-08-21。
本基準情形採用預設假設,不構成投資建議。當目標 PE 或盈餘成長率變化時,公允價值會顯著改變。開啟計算器可設定你自己的假設,並查看完整的敏感度區間。
UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services. It facilitates access to networks of specialist care providers, offers health management programs, direct care delivery, consumer engagement initiatives, and financial services. Its diverse clientele includes individuals (served directly through care systems), employers, insurance payers, and government organizations. Optum Insight specializes in providing technology, information, and consulting services to the healthcare industry. Its offerings include software and data products, advisory consulting arrangements, and outsourced managed services. Clients span hospital systems, physicians, health plans, governmental bodies, life sciences companies, and other relevant organizations. Finally, Optum Rx handles the company's pharmaceutical care services. This segment manages retail pharmacy networks, provides home prescription delivery, and offers specialty and compounding pharmacy capabilities. Leveraging its purchasing power and clinical expertise, Optum Rx also develops advanced programs related to step therapy, formulary management, medication adherence, and integrated disease and drug therapy management. UnitedHealth Group Incorporated, founded in 1977, has its corporate headquarters located in Minnetonka, Minnesota.
PE Ratio (TTM)
25.1x
PEG Ratio
n/m
獲利收益率
4.00%
ROE (TTM)
14.4%
Revenue/Share (TTM)
$496.83
股息收益率
2.29%
Debt/Equity
0.70x
UNH 的過去 12 個月本益比反映投資者為 UnitedHealth Group Incorporated 每一美元收益所支付的價格。該指標在與Medical - Healthcare Plans同類公司和公司自身歷史區間對比時最有意義。
UNH 的本益比 25.1x 結合 PEG 比率 -0.76 提供了成長調整後的視角。UNH 獲利為負,本益比和 PEG 比率此時均無意義,無法判斷股票被高估還是低估。注意 PE 估值最適合獲利穩定的成熟公司——對於高成長或週期性Medical - Healthcare Plans,DCF 分析可能更合適。
對 UnitedHealth Group Incorporated 使用 PE 估值的步驟:(1) 將目前本益比 (25.1x)與Medical - Healthcare Plans中位數對比評估相對定價,(2) 查看 PEG 比率 (-0.76)以調整成長預期,(3) 參考 5 年 PE 歷史區間判斷目前位置,(4) 用目標 PE 乘以前瞻 EPS 估算公允價值。這種相對估值方法與 DCF 的絕對估值互為補充。
UNH 的 PEG 比率為 -0.76,由本益比(25.1x)除以預期獲利成長率計算。由於 UNH 獲利為負,其 PEG 比率沒有意義,不應被解讀為低估或高估的訊號。注意 PEG 的準確性取決於成長預期的可靠性。
PE 本益比給出快速的相對定價——UNH 相對於Medical - Healthcare Plans同類的估值水準。DCF 基於預期自由現金流提供絕對價值。建議用 PE 做快速篩選,用 DCF 做深度分析。兩種方法各有盲區:PE 忽略了資本結構和現金流品質,DCF 則對成長率和折現率假設非常敏感。
本益比與 DCF 使用不同的方法和假設為 UNH 估值,因此兩者的結論可能不同。可對比 DCF 內在價值。
價格截至 2026-08-21。 財務數據來自 Financial Modeling Prep(過去 12 個月)· 估值方法論由 Charlie Wang 提供。
這是估計值,不構成投資建議。